In 2023, Medivation/Astellas Pharma’s Xtandi Will Be the Top-Selling Agent in the Prostate Cancer Market Across the United States, Europe, and Japan

In 2023, Medivation/Astellas Pharma’s Xtandi Will Be the Top-Selling Representative in the Prostate Cancer cells Market Across the … Today – 17:08 GMT BURLINGTON, Mass., Oct. 30, 2014/ PRNewswire/– Decision Resources Group discovers that Medivation/Astellas Pharma’s Xtandi will be the sales-leading representative across the globe’s major markets for prostate cancer, [...] Read More